Assessing methods of measuring medication adherence in chronically ill children—a narrative review

Linda Al-Hassany 1
Sanne M Kloosterboer 1
Bram Dierckx 2
Birgit CP Koch 1

1 Erasmus MC, University Medical Center Rotterdam, Department of Hospital Pharmacy, Rotterdam, The Netherlands; 2 Erasmus MC, University Medical Center Rotterdam, Department Child and Adolescent Psychiatry, Rotterdam, The Netherlands

Abstract: Nonadherence in children who use long-term medication is a serious problem and assessing adherence is an important step to provide solutions to this problem. Medication adherence can be measured by several methods, including (a) self-report questionnaires or structured interviews, (b) therapeutic drug monitoring (TDM), (c) electronic devices, and (d) pick-up/refill rates. The objective of this narrative review is to provide an overview of the literature about methods for the measurement of medication adherence in chronically ill children and adolescents. Therefore, we conducted a literature search by using multiple databases. Four methods of monitoring medication adherence are presented for the most described chronic diseases: asthma, HIV/AIDS, epilepsy, diabetes mellitus and ADHD. First, 10 commonly used self-report questionnaires and structured interviews are described, including the main characteristics, (dis)advantages and their validation studies. Second, the use of TDM in pediatric trials for medication adherence measurement is discussed. New sampling methods (e.g. dried blood spot) and sampling matrices (e.g. hair, saliva and urine) have shown their benefits for TDM in children. Third, electronic devices to measure medication adherence in children are presented, being developed for several drug administration routes. Fourth, the analyses, advantages and disadvantages of pharmacy data are discussed. The usage of this data requires specific calculations and interpretations to assess adherence. As presented in this review, every adherence method has specific (dis)advantages. When deciding which adherence method is applicable, validity and generalizability should be taken into account. Combining multiple methods seems to offer the best solution in the daily clinical practice.

Keywords: adherence, children, chronic illness, measurement, medication, (general) pediatrics

Introduction

With a prevalence of 26.6% and rising among children in 2006, chronic diseases are a main contributor to both morbidity and mortality. Pharmacological therapy is often essential for the treatment of these chronic diseases to prevent further deterioration. However, for effective pharmacological treatment, medication adherence is of great importance. Medication adherence is suggested to be even more important in the pediatric population. Moreover, medication adherence in children with chronic illnesses is more complex than adherence in adult populations. Several causes might contribute, including the lack of physical capacity or cognitive understanding which impedes self-administration by children. Also, child resistance is not uncommon, especially in the case of aversive formulations and time-consuming medical therapies. Cultural beliefs of parents and caregivers about treatments, the
role of family size and parental marital status are examples of other contributing factors to pediatric adherence.5,6

These factors highlight a complex influence on measuring medication adherence in minors, caused by the children’s (mainly infants and toddlers) dependency on parents and caregivers. As such, two extra elements are added to the (usual) therapeutic relationship between medical professionals and the patient: communicative interactions between parent and child, and between parent and professionals. This leads to a “therapeutic triad partnership” in pediatric care.5–7

Medication nonadherence can have serious consequences, including failure of therapy. The specific consequences of failure of therapy logically depend on the prescribed pharmacological treatment. For example, nonadherence of methylphenidate may cause less attention and more hyperactivity, and thus decreased cognitive performance.8 However, nonadherence of antiretroviral therapy can have possible life-threatening consequences as it predicts virologic suppression among HIV-positive patients.9 Besides failure of therapy, nonadherence can also lead to toxicity and pharmacological interactions. In this way, medication nonadherence might increase morbidity and mortality, and negatively impact the health-care costs.10–13

Despite the importance of medication adherence, nonadherence is very common among children and adolescents. Only 58% medication adherence has previously been reported in children who use long-term medication.13 Therefore, monitoring of medication adherence is of great importance.

Several different approaches to monitor medication adherence have been developed. These include (a) self-report questionnaires or structured interviews, (b) therapeutic drug monitoring (TDM), (c) electronic devices and (d) pharmacy pick-up/refill rates.14,15 TDM refers to the measurement of drugs in the patient’s body fluids, often in the bloodstream, with the aim of optimizing individual dosage regimens.16 Pick-up and refill rates include pharmacy-dispensing records to assess adherence.14

Unfortunately, no complete overview of options for drug adherence in children and adolescents is currently available. Previously published reviews did not discuss TDM or focus solely on questionnaires in this population.17,18 Other reviews tend to focus only on specific disorders and/or therapies, for example, asthma.19

Therefore the objective of this narrative review is to provide a comprehensive overview of the literature concerning measuring methods of medication adherence in chronically ill children. This review focuses on the usage of these methods in the daily clinical practice, with a special focus on the five most common chronic conditions which our search retrieved: asthma, HIV/AIDS, epilepsy, diabetes mellitus, and attention deficit hyperactivity disorder (ADHD). The outcomes of this review mainly concern an overview of the strengths and weaknesses of the medication adherence assessment methods, along with a description of recent developments.

Methods
We conducted a literature search in the following databases: Embase.com, Medline Ovid (PubMed), Web of Science, Cochrane Central and Google Scholar. The search terms and their corresponding synonyms used were: adherence, assessment, drug therapy, questionnaires, TDM, electronic devices, pick-up/refill rates, and children/adolescents. These search strategies did not contain any restrictions in time frame or in the type of study.

Studies that primarily focused on medication adherence measurement methods in children and adolescents with chronic diseases (i.e. with medication used for at least one month), were selected. Additional articles were also selected by screening the references of included articles.

For the statistical tests that were used for the validation of questionnaires, P-values less than 0.05 have been consistently considered as significant.

Results
The five most prominent diseases with the most retrieved articles and which have been described the most in literature are presented: asthma, HIV/AIDS, epilepsy, diabetes mellitus and ADHD. The largest amount of articles mentioned the use of (specific) questionnaires and the fewest number of articles described pick-up and refill rates as a method to measure medication adherence in children.

Questionnaires and structured interviews
Self-report questionnaires are considered a convenient, indirect and efficient method to measure adherence among patients. The biggest advantages of using questionnaires are their easy applicability in the clinical practice and low cost.20 However, questionnaires might be subject to recall and response bias which might decrease their accuracy and validity. Furthermore, due to the patients fear of disappointing doctors, results of questionnaires might lead to an overestimation of the level of adherence.21
In total, our search retrieved 10 validated and well-described questionnaires, which are listed in Table 1. Structured interviews have been included as well. Additional specifications of these questionnaires, such as the number of questions, validation and (dis)advantages are presented in Table 2. Methodological limitations of the concerning studies next to restrictions of the questionnaires are also presented in Table 2.

As can be seen, the questionnaires have been developed both for parents and for children. Furthermore, the questionnaires and structured interviews have been validated in different research populations, using various outcome measures. It is remarkable that the validation processes of the questionnaires and structured interviews have been performed in various manners.

A general questionnaire, which can be applied to different chronic diseases, is the “Chronic Disease Compliance Instrument” (CDCI). It was tested in diabetics first, but later adjusted to an English version and made available in patients (mainly adolescents) with rheumatoid arthritis, asthma and epilepsy. The development of this instrument and the associated different phases have been described extensively by Kyngäs et al.\(^\text{22}\) The CDCI can be used both for clinical and research purposes and—depending on the version—the compliance item has a Cronbach’s \(\alpha\) value (correlation coefficient) ranging from 0.78 to 0.86.

**Therapeutic drug monitoring**

TDM comprises measurement of drug concentrations in body fluids, often serum and plasma, of an individual patient. TDM is more often used as a tailored drug management tool to adjust doses in the optimal target range, than as a method to monitor drug adherence.\(^\text{23}\) However, TDM is the only direct objective measure of medication adherence and has thus been used for this purpose in scientific research, for example, in the therapeutic management of HIV-infected children.\(^\text{24}\)

Unfortunately, clinical research on TDM in children has been an underdeveloped area. Data and reference values on TDM in children are limited.\(^\text{25}\) Results from adult pharmacokinetic studies cannot be simply extrapolated to children, as physiological and biochemical differences lead to different pharmacokinetics and, thus, interpretation of drug concentrations.\(^\text{26}\)

However, for some agents a clear pharmacokinetic profile in children is known. For certain anti-epileptic drugs (AEDs), TDM is a reliable tool for clinicians in order to optimize drug dosing in children and measure adherence.\(^\text{27}\)

An important disadvantage of TDM is its invasive method of sampling. Children especially might experience a high level of anxiety when a venepuncture is conducted.\(^\text{28}\) Therefore, less invasive and more convenient methods of sample collection have been explored for this population. A range of these alternative sampling methods may serve as a solution for the difficulties encountered in the implementation of TDM in pediatric populations, as they might be less invasive compared to the conventional venepuncture.

Firstly, the dried blood spot (DBS) is a method which uses a simple prick in the finger, toe or heel for the collection of one drop of blood on a filter paper. DBS was initially developed as a screening method for metabolic defects in newborns, and is now being applied for TDM for a wide spectrum of drugs.\(^\text{29}\) A main advantage of this method is that less blood volume is needed, thus reducing the risk of transferring infections and pathogens.\(^\text{29}\) Moreover, its applicability in the home setting makes the DBS a convenient and flexible tool to collect blood, which leads to a reduction in the total costs as well.\(^\text{30}\)

Secondly, samples of other matrices have also been used for the assessment of adherence, including, saliva, scalp hair, tears, and urine.\(^\text{23}\) Saliva is described as a suitable matrix to measure asthma medication and anticonvulsants. However, saliva is not a good representation of the plasma concentration for all anticonvulsants, e.g. valproic acid (or valproate sodium) and phenobarbital.\(^\text{31-33}\) For hair, a more recent study (Prasitsuebsai et al) showed the association between antiviral drug concentrations (lopinavir/ritonavir regimens) in hair and virologic outcomes, while adherence measured by self-reports, drug plasma levels and pill counts did not show an association with virological success.\(^\text{34}\) The main advantage of hair sampling, beside its easiness, is the detection of longer-term compliance in HIV-infected children.\(^\text{33}\) Interestingly, Guillet et al have used the collection of urine samples to detect the presence of phenobarbital in neonates.\(^\text{35}\) However, more research on the relationship in other populations, e.g. older children and children with decreased renal function, is needed.\(^\text{35}\)

Although it is beyond the scope of TDM, sputum eosinophil count has been described as a guidance to assess compliance in patients using corticosteroid treatment to control their asthma as well.\(^\text{36}\) Also, the simpler measurements of increased exhaled nitric oxide (FeNO) levels have been found to be related to lower rates of medication adherence and, therefore, serve as a useful clinical tool.\(^\text{37,38}\)
| Authors                          | Year | Sample size | Mean age of the children ± SD (if provided) | Adherence assessment                                                                 | Filled in by/ persons being interviewed | Medicine                                                                 |
|---------------------------------|------|-------------|---------------------------------------------|--------------------------------------------------------------------------------------|------------------------------------------|--------------------------------------------------------------------------|
| **Asthma**                      |      |             |                                             |                                                                                      |                                          |                                                                          |
| Martinez, Sossa, and Rand       | 2007 | 64          | 3.6±2.2 years                               | Pediatric Inhaler Adherence Questionnaire (PIAQ)                                     | Parents/caregivers                       | Not mentioned (metered-dose inhaler, MDI)                                 |
| Tiggelman, van de Ven, van Schayck, Engels | 2015 | 139         | 11.8±1.0 years                              | Medication Adherence Report Scale for Asthma (MARS-A)                                | Children (adolescents)                   | Not mentioned Cohen et al (2009) reported self-reported adherence with inhaled corticosteroids (ICS) |
| Garcia-Marcos, Brand, Kaptein, and Klok | 2016 | 133         | 6 years (with a range of 2–12 years)        | Medication Adherence Report Scale (MARS-5)                                          | Parents                                  | Inhaled corticosteroids (ICS) (low-to-moderate doses of fluticasone propionate) |
| McQuaid, Walders, Kopel, Fritz, and Klinnert | 2005 | 115         | 11.5 years (with a range of 7–16 years)     | Family Asthma Management System Scale (FAMSS) Revised version                        | (Older) children and parents            | Not mentioned                                                             |
| **HIV/AIDS**                    |      |             |                                             |                                                                                      |                                          |                                                                          |
| Farley, Hines, Musk, Ferrus, and Tepper | 2003 | 26          | 6.9±3.2 years (with a range of 21 months to 12.5 years) | Pediatric AIDS Clinical Trials Group (PACTG) Module 1 and 2                          | Caregivers                               | (Three or more) highly active antiretroviral therapy (HAART) medications |
| **Epilepsy**                    |      |             |                                             |                                                                                      |                                          |                                                                          |
| Modi, Monahan, Daniels, and Glauser | 2010 | 119         | 7.2±2.9 years                               | Pediatric Epilepsy Medication Self-Management Questionnaire (PEMSQ)                 | Caregivers                               | Antiepileptic drugs—AED (carbamazepine/carbatrol, valproic acid, levetiracetam, oxcarbazepine, ethosuximide, gabapentin, lamotrigine, topiramate) |

(Continued)
| Table 1 (Continued). |
|----------------------|
| **Diabetes mellitus** |
| Authors | Year | Sample size | Mean age of the children ± SD (if provided) | Adherence assessment | Filled in by/ persons being interviewed | Medicine |
| Lewin, LaGreca, Geffken, Williams, Duke, Storch, and Silverstein | 2009 | 164 | 14.6±2.9 years (with a range of 11–18 years) | Selfcare inventory (SCI) | Adolescents and parents | Intensive regimens, continuous subcutaneous insulin infusion and glargine regimens |
| Lewin, Storch, Williams, Duke, Silverstein, and Geffken | 2010 | 275 parents along with their child (1 parent per child) 105 families of youths | 13.3±2.7 years 11.6±1.2 years (with a range of 6.1–15.8 years) | Diabetes Self-management Profile (DSMP) | Youth and parents, administered by a trained clinician | Insulin (various delivery methods) |
| Markowitz, Laffel, Volkening, Anderson, Nansel, Weissberg-Benchell, and Wysocki | 2011 | 338 | 12.5±1.7 years (with a range of 9–15 years) | Diabetes Self-management Questionnaire (DSMQ) | Children and their parents (two parallel versions) | All insulin regimens (by injections and by pump therapy) |

**ADHD**

| Authors | Year | Sample size | Mean age of the children ± SD (if provided) | Adherence assessment | Filled in by/ persons being interviewed | Medicine |
| Charach, Gajaria, Skyba, and Chen | 2008 | 19 | 11.85±2.1 years (with a range of 8.2–15.5 years) | Stimulant adherence measure | Parents and children | Psychostimulant medication for DSM-IV attention-deficit/hyperactivity disorder (ADHD) |

**Notes:**
- The MARS-5 is a shortened version of the MARS-A questionnaire.
- The search strategy originally retrieved the article by Lewin et al. However, as it is not the purpose of this article to examine the validity of the DSMP, but to provide normative data, information originating from the article by Harris et al has been mentioned in the Tables 1 and 2.

**Abbreviations:**
- PI AQ, Pediatric Inhaler Adherence Questionnaire;
- MARS-A, medication adherence report scale for asthma;
- MARS-5, medication adherence report scale;
- EMD, electronic monitoring devices;
- FAMSS, family asthma management system scale;
- PAC TG, Pediatric AIDS Clinical Trials Group;
- MEMS, medication event monitoring system;
- PE MS Q, pediatric epilepsy medication self-management questionnaire;
- SCI, selfcare inventory;
- DSMP, diabetes self-management profile;
- DSMQ, diabetes self-management questionnaire;
- ICC, intraclass correlation coefficient.
Table 2 Clinical relevant characteristics of all the validated questionnaires

| Adherence Assessment | Amount of questions | Optional: comparison with | Validation | Main advantages of the questionnaire | Main limitations of the study or specific disadvantages of the concerning questionnaire |
|----------------------|---------------------|---------------------------|------------|--------------------------------------|----------------------------------------------------------------------------------|
| **Asthma**           |                     |                           |            |                                      |                                                                                  |
| Pediatric Inhaler Adherence Questionnaire (PIAQ)\(^{17}\) | 6 questions (last 2 questions can be omitted in clinical practice) | The weight of inhaler canisters | Spearman's rho: 0.42 (significant)  
Sensitivity: 50–75%  
Positive predictive value: 23.1–66.7%  
Likelihood ratio to detect nonadherent patients: 1.5–5.5 (nonsignificant CIs) | Brief and easy (required time to fill in: 1–3 minutes) | Validated only in a Spanish-speaking population  
The chosen gold standard (change in canister weight) is vulnerable to deceit as well  
Adherence has been assessed during a short period of time (15 days), which however minimizes memory and social biases |
| Medication adherence report scale for asthma (MARS-A)\(^{7,74}\) | 10 questions | Cohen et al (2009): electronic adherence (an MDI-log monitor) | Cronbach's α: 0.80  
Cronbach's α: 0.85 (English language) and 0.86 (Spanish language)  
Test-retest reliability: r=0.65 (significant)  
Significant correlation between continuous MARS-A scores and continuous electronic adherence: r=0.42  
Dichotomized high self-reported adherence predicts high electronic adherence significantly: OR=1.06 | Cohen et al (2009):  
Strong overall psychometric properties (good internal, criterion and construct validity) | The criterion validity test has been performed in a relatively small sample of patients (n=53)  
Unknown generalizability of the results to other settings (for example populations with a lower burden of asthma)  
Further validation in Spanish-speaking populations is needed |
| Medication adherence report scale (MARS-5)\(^{73}\) | 5 questions | Validated electronic monitoring devices (EMD): Smartinhaeler\(^{°}\) and SmartDisk\(^{®}\) EMDs | Spearman's rho: 0.47 (significant); however, a variation of adherence rates at every MARS-5 score is shown by a scatter plot in the article  
Area under the ROC curve: 0.7188 and likelihood ratios which are too small to be clinically useful | Avoids social desirable answers/bias by its anonymity  
Long (12 months) real-life study without intervention | Poor accuracy and reliability compared with electronic monitoring (not a useful adherence measure in clinical practice)  
Unknown generalizability, as the study only included a sample from a Caucasian middle-class population without follow-up |

(Continued)
### Table 2 (Continued).

| Adherence Assessment                                      | Amount of questions | Optional: comparison with | Validation                                                                                                                                   | Main advantages of the questionnaire                                                                 | Main limitations of the study or specific disadvantages of the concerning questionnaire |
|-----------------------------------------------------------|---------------------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| **Family asthma management system scale (FAMSS)\(^76\)** | 7 core and 2 additional scales | MDILog electronic medication monitor | ● Cronbach’s $\alpha$: 0.84  
● Relationship between FAMSS summary score and MDILog medication adherence: 0.29 (significant)  
● Relationship between Medication adherence (one of the subscales) and MDILog medication adherence: 0.30 (significant) | ● FAMSS places adherence in a larger setting, as it includes the management of asthma in a family context—resulting in the provision of rich clinical data  
● The FAMSS summary score is related to (prospective) asthma morbidity | ● FAMSS is semi structured and costs more labour to implement than standardized self-reports  
● The authors used a small sample participating in the MDILog electronic medication monitor assessment  
● Research on the utility of the (translation of) FAMSS in a Spanish-speaking population has not been performed |
| **HIV/AIDS**                                              |                     |                           |                                                                                                                                            |                                                                                                           |                                                                                          |
| Pediatric AIDS Clinical Trials Group (PACTG) (Modules 1 and 2)\(^77\)  
Note: the PACTG is a measure which consists of an (oral) interview | Module 1: 7 questions  
Module 2: 4 questions\(^b\) | Viral load/virological response (and medication event monitoring system (MEMS\(^8\))) | ● Sensitivity: 90\%  
● Specificity: 43\%  
● Positive predictive value: 69\% | Not mentioned                                                                                                                                  | Not mentioned                                                                                           |
| **Epilepsy**                                              |                     |                           |                                                                                                                                            |                                                                                                           |                                                                                          |
| Pediatric Epilepsy Medication Self-Management Questionnaire (PEMSQ)\(^8\) | 27 items, consisting of 4 scales | MEMS\(^8\) TrackCap and self-reported adherence (a particular question answered by caregivers about the amount of missed AED doses in the past week) | ● Cronbach’s $\alpha$ of the scale “adherence to medications and clinic appointments”: 0.87  
● Association of the scale “adherence to medications and clinic appointments” with adherence measured by MEMS\(^8\): $r=0.22$ (significant)  
● Association of the scale “adherence to medications and clinic appointments” with self-reported adherence: $r=0.28$ (significant) | ● Strong psychometric properties  
● The PEMSQ also measures knowledge and expectations (perceptions) of epilepsy treatment, next to barriers to adherence and beliefs about the efficacy of medication\(^c\)  
● Brief measure and easy to perform and interpret | ● Limitations in the chosen population of the study: solely children below 14 years have been included from only one hospital, who also were within the first 2 years of their diagnosis |

\(^a\) Continued
| Adherence Assessment | Amount of questions | Optional: comparison with | Validation | Main advantages of the questionnaire | Main limitations of the study or specific disadvantages of the concerning questionnaire |
|----------------------|---------------------|--------------------------|------------|--------------------------------------|--------------------------------------------------------------------------------|
| **Diabetes mellitus**<sup>29</sup> | 14 items | HbA1c assay in blood (and the hereafter mentioned diabetes self-management profile (DSMP)) | • Cronbach’s α: 0.72 (parent) and 0.80 (adolescent)  
• Agreement between parent and adolescent: ICC (intraclass correlation coefficient) = 0.47  
• Test-retest reliability: r=0.91 (adolescent, significant) and r=0.86 (parent, significant) | • Strong psychometric properties  
• The SCI assesses different key aspects of the regimen and adherence behaviors in diabetics  
• SCI can be applied to a variety of insulin regimens  
• Time (and cost) effective | • Limited generalizability, due to the restricted sample characteristics (mostly Caucasian, wide age range, from the low to lower-middleclass) |
| **Self-care inventory (SCI)**<sup>30</sup> | 23 items with 5 domains | HbA1c assay in blood | • Cronbach’s α: 0.78 (parent) and 0.75 (child)  
• Cronbach α=0.76  
• Test-retest reliability (Pearson correlation) over 3 months: r=0.67  
• Agreement between parent and adolescent (Pearson correlation): r=0.61 | • Strong psychometric properties (acceptable construct validity and reliability)  
• Relatively convenient to administer and interpret  
• The DSMP includes different components and dimensions concerning self-management of the disease (next to the administration of insulin)  
• It predicts additional variance in metabolic control (HbA1c)  
• Includes two versions, distinguishing different treatment regimens | DSMP requires quite some effort from staff and patients (20–30 minutes) |

<sup>29</sup>First mentioned by Harris et al (2000)[61]

<sup>30</sup>Note: the DSMP is a measure which consists of an (oral) interview
Table 2 (Continued).

| Adherence Assessment                                      | Amount of questions | Optional: comparison with | Validation                                                                                     | Main advantages of the questionnaire                                                                 | Main limitations of the study or specific disadvantages of the concerning questionnaire |
|-----------------------------------------------------------|---------------------|--------------------------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Diabetes Self-Management Questionnaire (DSMQ)¹             | 9 items             | HbA₁c assay in blood Also: frequency of blood glucose monitoring in blood and the dose of insulin (next to other measures which are correlated with adherence and control of the blood glucose levels, for example the DSMP)¹ | • Cronbach’s α: 0.59 for children (with Cronbach’s α: 0.56 for children <11 years and with Cronbach’s α: 0.60 for children ≥11 years) and 0.57 for parents | • Short questionnaire (can be completed in <10 minutes)                                          | • Compared with the DSMP, the shortness of the DSMQ might negatively impact its internal consistency |
|                                                           |                     |                          | • Significant correlation with HbA₁c for children ≥11 years (r=−0.22)                          | • Requires not a lot of staff (labour/resources)                                                          | • Does not include two versions to take the different regimes into account, which might lead to loss of adherence information related to these regimes |
|                                                           |                     |                          | • Significant correlation with the frequency of blood glucose monitoring for children <11 years (r=0.22) and for children ≥11 years (r=0.44) | • Advantages of the chosen population in this study: DSMQ is validated in a diverse and younger population (diverse geographical origins and ethnic backgrounds, aged 9–15 years) |

ADHD

| Stimulant Adherence Measure Note: the Stimulant Adherence Measure consists of a semi-structured telephone interview | Parent version² first section: 9 questions second section: 4 questions third section: 1 question | MEMS®                                                                                     | Significant intraclass correlations (ICCs), varying from 0.663–0.907, between data derived from MEMS® and reports from parents in week 1, 2 and 3 and in the months 1, 2 and 3 | Valid and reliable questionnaire, as shown by the results | More accurate for adherence ratings from parents than from children |
|                                                                                                                                  | Child version³ first section: 14 questions, second section: 3 questions, third section: 1 question |                                                                           | Significant ICC’s between data derived from MEMS® and reports from children in week 1 (ICC=0.773), week 2 (ICC=0.542) and week 3 (ICC=0.606) | Results show comparable adherence measurements of the questionnaire, administered at monthly intervals, compared with MEMS® | Limitations of the sample: small sized and derived from a clinical setting (it is not a community-based research population) |
|                                                                                                                                  |                                                                                                     |                                                                           | Significant inter-rater reliability (ICC=0.956)                                                       | The stimulant adherence measure offers the opportunity to explanation (of behavior) | | Notes: *Tiggelman et al.¹³ have translated the MARS-A to a Dutch population of adolescents, as this questionnaire was first described in adults by Cohen et al.¹⁴ Therefore, Table 2 describes the main characteristics of MARS-A according to Cohen et al.¹⁴ According to the available questionnaires with the form date in November 2004, which can be found at: https://www.frontierscience.org/apps/cfmx/apps/common/QOLAdherenceForms/index.cfm?project=IMPAACT. Although questionnaires which measure (subjective) perceptions of the disease have been an exclusion criterion, the presence of these additional scales might lead to a better understanding of parental beliefs and (deficiencies of) knowledge, which contribute to self-management and the therapy of the child. Therefore, this is considered to be an advantage.¹⁵ The DSMP is an update of the self-care adherence inventory (SCAI).¹⁶ The DSMQ is a shortened version of the DSMQ, which also reflects the medication adherence of a broader age range. Both questionnaires show a significant correlation; however, these correlations have not been mentioned or elaborated on in the tables.² According to the version published at: https://www.sickkids.ca/pdfs/Psychiatry/SAM/8621-sam_parent.pdf² According to the version, published at: https://www.sickkids.ca/pdfs/Psychiatry/SAM/8620-sam_child.pdf Abbreviations: PIAQ, pediatric inhaler adherence questionnaire; MARS-A, medication adherence report scale for asthma; MARS-5, medication adherence report scale; EMD, electronic monitoring devices; FAMSS, family asthma management system scale; PACTG, Pediatric AIDS Clinical Trials Group; MEMS®, medication event monitoring system; PEMSQ, pediatric epilepsy medication self-management questionnaire; SCL, self-care inventory; DSMP, diabetes self-management profile; DSMQ, diabetes self-management questionnaire; ICC, intraclass correlation coefficient. |
Electronic medication monitoring

With technological improvements made in health care since the early 1990s, the invention of electronic monitors to assess adherence has been a valuable addition to the existing pediatric adherence measurement methods. Electronic adherence measurement devices have been even regarded as the “gold standard” of adherence measurement. 39,40

General systems

Ingerski et al have provided an extensive overview of electronic monitors, separated for each illness group in pediatric populations. 41 As mentioned by Ingerski et al, electronic monitors can be categorized into three main groups: the oral medication monitors, the inhaled medication monitors, and the nebulized medication monitors. 41

Oral medication monitors consist of the electronic drug exposure monitor (eDEM) or the similar, but newer and well-known device medication event monitoring system (MEMS®; Aardex Group, Seraing, Belgium). It consists of a computer chip in the bottle cap, which records the date and time each time the pill bottle is opened. 41,42 Moreover, MedSignals® (MedSignals/VitalSignals LLC, Lexington, KY, USA) is an electronic pill box which aids in the management of medication intake by providing real-time feedback on the patient’s adherence. 41

Examples of inhaled medication monitors consist of the DOSER (MediTrack Products LLC, South Easton, MA, USA), Medtrack metered-dose inhaler (MDI) Chronolog, MDILOG (Westmed, Inc., Tucson, AZ, USA) and the Smartinhaler Tracker (Adherium Ltd, Auckland, New Zealand). Moreover, a couple of monitors have been described which measure nebulized medication: I-neb adaptive aerosol delivery (AAD) or the HaloLite nebulizer (Respironics, Chichester, UK/Respironics Respiratory Drug Delivery, Cedar Grove, NJ, USA) and the Nebulizer Chronolog (Forefront Technologies Inc, Lakewood, CO, USA), for example. 41

New systems

An important and more recent development is the real-time medication monitoring (RTMM) system, which registers the number of inhaled corticosteroids for example. By connecting this system to a pressurised metered-dose inhaler (pMDI), time and the date of the given (inhaled) doses can be measured. The collection of the obtained data occurs by sending them to a study database through a mobile telephone network. 43,44

The real-time wireless electronic adherence monitor (EAM) has been described in a HIV-infected population as well. Haberer et al have mentioned this way of monitoring as a feasible and a valid method—considering the opportunity it offers to intervene with adherence challenges directly, although it does have its technical and cost-related difficulties. 45

Lastly, the multifunctionality of electronic mobile devices (smartphones) has been shown to be useful in the measurement and improvement of adherence in the short-term. Reminder systems, for example, short message service (SMS) text messages, can be synced with monitoring devices. Synchronization of these smartphones might also facilitate transmission of data from monitoring devices to patients or physicians. 46,47

Primary advantages and disadvantages

Next to the noninvasive measurement of adherence, electronic monitors could serve other purposes, including helping the patient to handle complex dosing regimens and dose timings. 41 An extra advantage in pediatric populations is the possibility to divide responsibilities of medication dispersion within families. However, they often do not monitor the actual ingestion of medications, have a chance of missing data, and due to their high costs, they are not routinely being used in the clinical setting. 48

Unfortunately, although validated in adult studies, data about the validation and reliability of these devices in a pediatric population has not always been provided. 41

Pick-up and refill rates

Pharmacy data may serve as a source for the calculation of pick-up rates and refill rates. Pick-up rates describe the number of picked-up prescriptions as a percent of the total prescribed doses. 49 Refill rates are defined as the division of the amount of days the drugs have been prescribed by the total calendar days of that period. 50 Several methods and approaches exist to estimate the medication refill rate. Vink et al compared these methods in an observational cohort study with a relatively old diabetic population (mean age 66 years). 51 Two methods were considered sensitive methods in case of multiple drug usage: the medication possession ratio (MPR) using a one-year fixed period or the maximal gap between refills (GAP). 51

Methodological transparency remains an important factor in the analyses using pharmacy claims data. 52 The different methods to calculate adherence by using pharmacy records lead to different adherence rates and should
therefore be mentioned and taken into account.\textsuperscript{49} Comparable studies for children have not been found.

As described earlier, the refill rate is defined as the number of days that a (particular) medicine has been dispensed to a patient in a defined period, divided by the total number of days in that time period. Pharmacy records have shown a good correlation to other compliance measures, for example, oral and written self-report measures. Moreover, their calculation is relatively easy and inexpensive.\textsuperscript{50,53}

However, important limitations of the usage of pick-up rates are mentioned by Mudd et al.\textsuperscript{54} Pharmacy records do not measure actual administration of the medication. For example, medication may be shared among members of a household.\textsuperscript{54} Another limitation is that adjustments of medication doses by the physician are not always reflected by these rates. Calculations of pick-up rates can thus also lead to an overestimation of the patient’s nonadherence, and false-positive results.

When interpreting pharmacy record data, it should be taken into account that current outcomes are better predicted than future outcomes. Also, a longer duration of this adherence assessment (more than six months) has been found to be more predictive for the future outcome.\textsuperscript{55}

Our search retrieved different sources to collect these pharmacy data. A difference can be made, for example, between Medicaid pharmacy data and data collected from individual pharmacies (also called “pharmacy record data”), which have been compared by Mudd et al.\textsuperscript{56} Most retrieved articles used adults as their research population and did not validate their method specifically in a chronically ill pediatric population.

**Discussion**

By performing a broad literature search using several databases, we provide an overview of the four main adherence measurement methods in chronically ill children: questionnaires and structured interviews, TDM, electronic devices and pick-up and refill rates. To provide helpful tools in measuring adherence in the clinical setting, we have focused on five main diseases among children.

In total, we have selected ten validated questionnaires for five chronic diseases. For most of the questionnaires, parents of caregivers are the assessor. Especially in chronically ill children, caregivers play an important role in the administration of medication. Therefore, the creation and usage of questionnaires which allow parents to say how they feel about medication usage without being judged or criticized, is highly important. An example of such a questionnaire is the Pediatric Inhaler Adherence Questionnaire (PIAQ).\textsuperscript{57} An indirect inquiry may be more effective to minimize socially desired, and thus biased behaviour, and eventual miscommunication.\textsuperscript{58}

A large amount of the found articles reported questionnaires and interviews which were not reusable to assess adherence, as their validity was unknown. This makes it impossible to evaluate these instruments. Furthermore, for the questionnaires that have been validated, the validation methods varied, making comparisons difficult. Cronbach’s $\alpha$ is an often-used measure for internal consistency and reliability of questionnaires. A questionnaire with Cronbach’s $\alpha >0.70$ is often considered as having a high internal consistency.\textsuperscript{59} Table 2 shows that this measure has not been provided for all instruments. On the contrary, the sensitivity, specificity, positive predictive values (which are not intrinsic to the questionnaire) and intraclass correlations (instead of the Pearson correlation coefficient) have been mentioned more commonly.\textsuperscript{60} Moreover, the duration of the validation studies differed remarkably. Also, a great variation in researched populations was observed, with diverse cultural and linguistic backgrounds. Several studies have described lower medication adherence rates in people with culturally and linguistically diverse backgrounds.\textsuperscript{44,61,62} We advise more unambiguity herein. Besides the statistical method, study population and duration of the validation study, the comparator should also be taken into account.

With regards to electronic medication monitoring, MEMS® are regarded as the golden standard in measuring adherence. However, not all instruments were pitted against this standard. Moreover, it can be questioned if this indeed is the best method available to assess medication adherence.\textsuperscript{63} Electronic adherence monitoring devices—which can be categorized into three main groups: the oral medication monitors, the inhaled medication monitors and the nebulized medication monitors—surely have their individual technical limitations and mechanical failures.\textsuperscript{41} Therefore, other methods should be considered as an useful comparator for medication adherence method validations, including TDM. New developments in the area of electronic monitoring include the Real Time Medication Monitoring (RTMM) system, and the real-time wireless Electronic Adherence Monitor (EAM), which offers the opportunity to potentially intervene with adherence challenges, as well as (the multi-functionality of) smartphones.

TDM might now be an undervalued adherence method, due to its invasiveness and the lack of knowledge about
the interpretation. However, TDM is the only direct objective measure of medication adherence. Moreover, due to recent developments in new sampling techniques and matrices like urine and hair, TDM might have become a very suitable and patient-friendly tool for adherence measurement in children. Also, this measure might be of great benefit for patients with mental diseases, for example schizophrenia, who may suffer from impaired disease awareness and social isolation, as most of these sample techniques can be applied at home.\(^{64,65}\) However, the applicability of these TDM assays is still limited, as more research about their validity should be performed.

The use of pharmacy records to calculate the pick-up rates or refill rates, in order to measure compliance, has shown to be relatively easy and inexpensive. It is striking that this adherence method was the least described method in the retrieved articles, probably due to the fact that not all pharmacy databases are standardized.\(^{17}\) Furthermore, the calculations should be interpreted with caution, as they do not show the actual administration of the prescribed drugs. This an important disadvantage of several electronic monitors as well.

Adherence measurement is important for outcomes in both, the clinical setting and the research domain. The choice for the most suitable adherence tool depends on the setting, the population, and validity of the adherence tool. Firstly, for a clinical setting, easy implementation in clinical routine is essential. For example, the usage of pharmacy records may be less practical, as the calculation of pick-up rates is time consuming. For the research setting, however, this might be less of a problem. Secondly, the population is of importance, including factors like age and type of disease. Adolescents with asthma might be able to assess their adherence with a questionnaire themselves, while for adolescents with cognitive disorders or alcohol addiction for example this is more problematic. Thirdly, the (external) validity, or the generalizability, is important. This applies to every adherence method, thus not only for questionnaires. Moreover, for example for TDM, it should be assessed what the certainty of non-adherence is when no drug can be detected in the blood.

As is stated in this review, every adherence measurement tool has its own advantages and disadvantages. The perfect method to measure medication adherence does not exist. Therefore, the usage of a combination of tools might offer the best solution.\(^{56}\) Combining a more subjective measurement method, for example questionnaires, with a more objective measurement method, for example TDM, might strengthen the assessment.\(^{67}\) Also different sources of information, i.e. children and parents, are of added value.

We recommend the validation of questionnaires, which are originally validated in adult populations, in children and adolescents as well - for example the Morisky Medication Adherence Scale. We also encourage different specialisations to learn from each other and to look to the applicability of advancements made in different specializations. Adherence measurement is not only important as non-adherence influences health outcomes; it also enables targeted interventions to improve medication adherence. Such interventions may include psycho-education or dosage reminders.\(^{68}\) Lastly, further research is required to examine the consistency among the different medication adherence methods and the level of agreement between reports of adherence from children and parents/caregivers.\(^{69,70}\)

A strength, but also a limitation of our review is the broad scope. It is striking that not all questionnaires, as presented by Quittner et al, have been found.\(^ {17}\) Our broad scope may have led to the consequence that not all relevant articles have been included and reviewed. Furthermore, we did not describe lesser used adherence tools, such as pill counts and home-visiting nurses, bottle/canister weights and daily diary methods, for example.\(^ {17,66,71,72}\) However, we conducted an extensive search in multiple databases and focused on different diseases, not limited to a specific condition or method. This provides an important update of earlier reviews on adherence measuring methods in paediatric populations.

**Conclusion**

We provide an updated narrative overview of four major methods to measure adherence in chronically ill children. By describing recent developments, next to the advantages and disadvantages, we give clinicians the tools to make a well-founded decision in choosing the right adherence method(s).

**Key points**

What is known:

- Medication adherence can be measured by several methods: self-report questionnaires (structured interviews), TDM, electronic devices and pick-up/refill rates. It is recommended to assess adherence by combining multiple adherence methods, while keeping their individual (dis)advantages in mind.

What is new:

- To provide a comprehensive and updated narrative review of the existing literature concerning measurement
methods of medication adherence in children and adolescents with a chronic illness.

The review focuses on the usage of these methods in pediatric populations with common chronic conditions: asthma, HIV/AIDS, epilepsy, diabetes mellitus and ADHD. With this overview, we aim to provide clinicians the tools to make the right decision when assessing adherence in the daily clinical practice.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Van Cleave J, Gottmacher SL, Perrin JM. Dynamics of obesity and chronic health conditions among children and youth. *Jama*. 2010;303(7):623–630. doi:10.1001/jama.2010.104

2. Epping-Jordan J, Bengoa R, Kawar R, Sabaté E. The challenge of chronic conditions: WHO responds. *Bmj*. 2001;323(7319):947–948. doi:10.1136/bmj.323.7319.947

3. DeSevo G, Klootwyk J. Pharmacologic issues in management of chronic disease. *Prim Care*. 2012;39(2):345–362. doi:10.1016/j.pop.2012.03.007

4. DiMatteo MR, Giordani PJ, Lepper HS, Crogan TW. Patient adherence and medical treatment outcomes: a meta-analysis. *Med Care*. 2002;40(9):794–811. doi:10.1097/00005656-200209000-00008

5. El-Rachidi S, LaRochelle JM, Morgan JA. Pharmacists and Pediatric Medication Adherence: bridging the Gap. *Hoop Pharm*. 2017;52(2):124–131. doi:10.1036/hp5202-124

6. Santer M, Ring N, Yardley L, et al. Treatment non-adherence in pediatric long-term medical conditions: systematic review and synthesis of qualitative studies of caregivers’ views. *BMC Pediatr*. 2014;14:63. doi:10.1186/1471-2431-14-82

7. DeCivita M, Dobkin PL. Pediatric adherence as a multidimensional and dynamic construct, involving a triadic partnership. *J Pediatr Psychol*. 2004;29(3):157–169.

8. Leonard BE, McCurtan D, White J, King DJ. Methylphenidate: a review of its neuropharmacological, neuropyschological and adverse clinical effects. *Hum Psychopharmacol*. 2004;19(3):151–180. doi:10.1002/hup.579

9. Paterson, D.L., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med*. 2000;133(1):21–30.

10. Iuga AO, McGuire MJ. Adherence and health care costs. *Risk Manag Healthc Policy*. 2014;7:35–44. doi:10.2147/RMHP.S19801

11. Matsui DM. Drug compliance in pediatrics: clinical and research issues. *Pediatr Clin North Am*. 1997;44(1):1–14

12. Dawood OT, Izhm M, Ibrahim M, Paiaan S. Medication compliance among children. *World J Pediatr*. 2010;6(3):200–202. doi:10.1007/s12519-010-00218-8

13. World Health Organization. Adherence to long-term therapies - evidence for action. Available from: http://apps.who.int/medicinedocs/en/ d/J4883e/. Accessed July 01, 2017.

14. Lam WY, Fresco P. Medication adherence measures: an overview. *Biomed Res Int*. 2015;1–12. doi:11055/2017/217047

15. Düssing R, Mengden T. Compliance with drug therapy—new answers to an old question. *Nephrol Dialysis Transplant*. 2001;16:1317–1321. doi:10.1093/ndt/16.7.1317

16. Kang JS, Lee MH. Overview of therapeutic drug monitoring. *Korean J Intern Med*. 2009;24(1):1–10. doi:10.4094/kjim.2009.24.1.1

17. Quittner AL, Modi AC, Lemanek KL, Ievors-Landis CE, Rapoff MA. Evidence-based assessment of adherence to medical treatments in pediatric psychology. *J Pediatr Psychol*. 2008;33(9):916–936. doi:10.1093/jpepsy/jsm064

18. Nguyen TM, La Caze A, Cottrell N. What are validated self-report adherence scales really measuring?: a systematic review. *Br J Clin Pharmacol*. 2014;77(3):427–445. doi:10.1111/bcp.12194

19. Jentzas N, Camargos PAM. Methods of assessing adherence to inhaled corticosteroid therapy in children and adolescents: adherence rates and their implications for clinical practice. *J Bras Pneumol*. 2008;34(8):614–621.

20. Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. *Transl Behav Med*. 2015;5(4):470–482. doi:10.1097/s13142-015-0313-2

21. Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. *Pharmacoeconomics*. 2010;28(12):1097–1107. doi:10.2165/11537400-000000000-00000

22. Kyngas HA, Skaa-Chandler CA, Dufty ME. The development of an instrument to measure the compliance of adolescents with a chronic disease. *J Adv Nurs*. 2000;32(6):1499–1506.

23. Johannotes SJ, Landmark CJ. Value of therapeutic drug monitoring in epilepsy. *Expert Rev Neurother*. 2008;8(6):929–939. doi:10.1586/14737157.8.6.929

24. Van Rossum AMC, Bergshoeff AS, Frauji PL, et al. Therapeutic drug monitoring of indinavir and nevirapine to assess adherence to therapy in human immunodeficiency virus-infected children. *Pediatr Infect Dis J*. 2002;21(8):743–747. doi:10.1097/01.inf.0000023962.00726.49

25. MacLeod S. Therapeutic drug monitoring in pediatrics: how do children differ? *Ther Drug Monit*. 2010;32(3):253–256. doi:10.1097/FTD.0b013e3181ddd51ef

26. Mahmood I. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. *Clin Pharmacokinet*. 2014;53(4):327–346. doi:10.1007/s40262-014-0134-5

27. Walson PD. Role of therapeutic drug monitoring (TDM) in pediatric anti-convulsant drug dosing. *Brain Develop*. 1994;16(1):23–26. doi:10.1016/0387-7604(94)90108-2

28. Fassler D, Wallace N. Childrens Fear of Needles. *Clin Pediatr (Philia)*. 1989;28(1):59–60. doi:10.1177/000992288202010112

29. Deep A, Kumar P, Kumar A, Thakkar AS. Dry blood spot technique: a review. *Int J Pharm Sci Res*. 2012;3(5):90–94.

30. Martial LC, Aarnoutse RE, Schreuder MF, et al. Cost evaluation of dry blood spot home sampling as compared to conventional sampling for therapeutic drug monitoring in children. *PLOS One*. 2016;11(12):e0176433. doi:10.1371/journal.pone.0176433

31. Lacy P, Lee JL, Vethanayagam D. Sputum analysis in diagnosis and management of obstructive airway diseases. *Ther Clin Risk Manag*. 2005;1(3):169–179.

32. Lena SM, Hutchins P, Wood CB, Turner P. Salivary theophylline monitoring DJ. Role of therapeutic drug monitoring (TDM) in pediatric anti-convulsant drug dosing. *Brain Develop*. 1994;16(1):23–26. doi:10.1016/0387-7604(94)90108-2

33. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. *Clin Pharmacokinet*. 1999;36(6):453–470. doi:10.2165/00003088-199936060-00006

34. Prasitsuebsai W, Kerr SJ, Truong KH, et al. Using lopinavir concentrations in hair samples to assess treatment outcomes on second-line regimes among asian children. *AIDS Res Hum Retroviruses*. 2015;31(10):1009–1014. doi:10.1098/AID.2015.0111

35. Guillert R, Kwon JM, Chen S, McDermott MP. Urine phenobarbital drug screening: potential use for compliance assessment in neonates. *J Child Neurol*. 2012;27(2):200–203. doi:10.1177/088307381146665
36. Parameswaran K, Leigh R, Hargreve FE. Sputum eosinophil count to assess compliance with corticosteroid therapy in asthma. J Allergy Clin Immunol. 1999;104(2):502–503.

37. Miraglia Del Giudice M, Marseglia GL, Leonardi S, et al. Fractional exhaled nitric oxide measurements in rhinitis and asthma in children. Int J Immunopathol Pharmacol. 2011;24(4 Suppl):29–32.

38. Vrijverberg SH, Koster ES. Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy-based study. Pediatr Allergy Immunol. 2012;23(6):529–536. doi:10.1111/j.1399-3098.2012.01279.x

39. Olivieri NF, Matsui D, Herrmann C, Koren G. Compliance assessed by the medication event monitoring system. Arch Dis Child. 1991;66(12):1399–1402. doi:10.1136/adc.66.12.1399

40. Matsui D, Herrmann C, Braudo M, Ito S, Olivieri N, Koren G. Clinical use of the medication event monitoring system: a new window into pediatric compliance. Clin Pharmacol Ther. 1992;52(1):102–103.

41. Ingerski LM, Hente EA, Modi AC, Hommel KA. Electronic measurement of medication adherence in pediatric chronic illness: a review of measures. J Pediatr. 2011;159(4):528–534. doi:10.1016/j.jpeds.2011.05.018

42. Ailinger RL, Black PL, Lima-Garcia N. Use of electronic monitoring in clinical nursing research. Clin Nurs Res. 2008;17(2):89–97. doi:10.1177/1054773808316941

43. Vasbinder EC, Janssens HM, Rutten-van Mölken MPMH, et al. Use of electronic monitoring of asthma therapy to improve compliance in children using a real-time medication monitoring system (RTMM): the e-MATIC study protocol. BMC Med Inform Decis Mak. 2013;13:38. doi:10.1186/1472-6947-13-38

44. Vasbinder E, Dahhan N, Wolf B, et al. The association of ethnicity and linguistically diverse backgrounds: a meta-analysis. Ann Pharmacother. 2010;44(6):964–982. doi:10.1345/aph.1M572

45. Grimes DE, Andrade RA, Niemeyer CR, Grimes RM. Measurement of medication adherence in pediatric chronic illness: a systematic review of the literature. J Am Med Inform Assoc. 2012;19(5):696–704. doi:10.1136/amiajnl-2011-000748

46. Haberer JE, Kiwanuka J, Nansera D, et al. Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. Aids. 2013;27(13):2166–2168. doi:10.1097/QAD.0b0133e32836353f3

47. Dayer L, Heldenbrand S, Anderson P, Gubbins PO, Martin BC. Smartphone medication adherence apps: potential benefits to patients and providers. J Am Pharm Assoc. 2003;53(2):172–181. doi:10.1331/JAPhA.2013.12202

48. Vervoort M, Linn AJ, van Weert JCM, de Bakker DH, Bouvy ML, van Dijk L. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. Arch Dis Child. 2012;97(5):696–704. doi:10.1136/archdischild-2011-300748

49. Riekert KA, Rand CS. Electronic monitoring of medication adherence: when is high-tech best? J Clin Psychol Med Settings. 2002;9(1):25–34. doi:10.1023/A:101431928789

50. Grimes DE, Andrade RA, Niemeyer CR, Grimes RM. Measurement issues in using pharmacy records to calculate adherence to antiretroviral drugs. HIV Clin Trials. 2013;14(2):68–74. doi:10.1310/hct1402-68

51. Rijken CAW, Tobi H, Vergouwen ACM, de Jong-van den Berg LTW. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients’ compliance by using computerised pharmacy data. Pharmacoepidemiol Drug Saf. 2004;13(6):365–370. doi:10.1002/pds.951

52. Vink NM, Klungel OH, Stolk RP, Denig P. Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf. 2009;18(2):159–165. doi:10.1002/pds.1698

53. Rickles NM, Svardstad BL. Relationships between multiple self-reported nonadherence measures and pharmacy records. Res Social Admin Pharm. 2007;3(4):363–377. doi:10.1016/j.sapharm.2006.11.001

54. Mudd K, Bollinger ME, Hsu VD, Donithan M, Butz A. Pharmacy fill patterns in young urban children with persistent asthma. J Asthma. 2006;43(8):597–600. doi:10.1080/02770900600878557

55. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2011;52(4):493–506. doi:10.1093/cid/ciq167

56. Mudd KE, Bollinger ME, Hsu VD, Manning A, Tsoukleris MG, Butz AM. Concordance of Medicaid and pharmacy record data in inner-city children with asthma. Contemp Clin Trials. 2008;29(1):13–20. doi:10.1016/j.cct.2007.05.002

57. Martinez CER, Sossa MP, Rand CS. Validation of a questionnaire for assessing adherence to metered-dose inhaler use in asthmatic children. Pediatr Asthma Allergy Immunol. 2007;20(4):243–253. doi:10.1089/ pai.2007.001

58. Charach A, Gajaria A, Skyba A, Chen S. Documenting adherence to psychostimulants in children with ADHD. J Can Acad Child Adolesc Psychiatry. 2008;17(3):131–136.

59. Modi AC, Monahan S, Daniels D, Glauer TA, Development and validation of the Pediatric Epilepsy Medication Self-Management Questionnaire. Epilepsy Behav. 2010;18(1–2):94–99. doi:10.1016/j.yebeh.2010.03.009

60. Heo M, Kim N, Faith MS. Statistical power as a function of Cronbach alpha of instrument questionnaire items. BMC Med Res Methodol. 2015;15(86). doi:10.1186/s12874-015-0092-0

61. Manias E, Williams A. Medication adherence in people of culturally and linguistically diverse backgrounds: a meta-analysis. Ann Pharmacother. 2010;44(6):964–982. doi:10.1345/aph.1M572

62. Diaz E, Woods SW, Rosenheck RA. Effects of ethnicity on psychotropic medications adherence. Community Ment Health J. 2005;41(5):521–537. doi:10.1007/s10597-005-6359-x

63. Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs. 1995;49(3):321–327. doi:10.2147/PROM.S42735

64. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence to medical treatments in childhood chronic illness: a systematic review. Arch Pediatr Adolesc Med. 2006;160(7):824–830. doi:10.1001/archpedi.160.7.824

65. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2006;167(5):450–550. doi:10.1001/archinte.167.5.540

66. Haberer JE, Cook A, Walker AS, et al. Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV Nondisclosure, and paradoxical income effects. PLoS One. 2011;6(4):e18505. doi:10.1371/journal.pone.0018505

67. Dolezel C, Mellins C, Brackis-Cott E, Abrams EJ. The reliability of reports of medical adherence from children with HIV and their adult caregivers. J Pediatr Psychol. 2003;28(5):355–361.

68. Kendrick R, Bayne JRD. Compliance with prescribed medication by elderly patients. Can Med Assoc J. 1982;127(10):961–962.

69. Kalichman SC, Amaral CM, Stearns H, et al. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med. 2007;22(7):1003–1006. doi:10.1007/s11606-007-0171-y
73. Tiggelman D, Van de Ven MOM, Van Schayck OCP, Engels RCME. Longitudinal associations between asthma control, medication adherence, and quality of life among adolescents: results from a cross-lagged analysis. Qual Life Res. 2015;24(9):2067–2074. doi:10.1007/s11136-015-0945-3

74. Cohen JL, Mann DM, Wisnivesky JP, et al. Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the medication adherence report scale for asthma. Ann Allergy, Asthma Immunol. 2009;103:325–331. doi:10.1016/S1081-1206(10)60532-7

75. Garcia-Marcos PW, Brand PLP, Kaptein AA, Klok T. Is the MARS questionnaire a reliable measure of medication adherence in childhood asthma? J Asthma. 2016;53(10):1085–1089. doi:10.1080/02770903.2016.1180699

76. McQuaid EL, Walders N, Kopel SJ, Fritz GK, Klinnert MD. Pediatric asthma management in the family context: the family asthma management system scale. J Pediatr Psychol. 2005;30(6):492–502. doi:10.1093/jpepsy/jsi074

77. Farley J, Hines S, Musk A, Ferrus S, Tepper V. Assessment of adherence to antiviral therapy in HIV-infected children using the medication event monitoring system, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J Acquired Immune Defic Syndr. 2003;33(2):211–218. doi:10.1097/00126334-200306010-00016

78. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109(4):e61. doi:10.1542/peds.109.4.e61

79. Lewin AB, LaGreca AM, Geffken GR, et al. Validity and reliability of an adolescent and parent rating scale of type 1 diabetes adherence behaviors: the Self-Care Inventory (SCI). J Pediatr Psychol. 2009;34(9):999–1007. doi:10.1093/jpepsy/jsp032

80. Lewin AB, Storch EA, Williams LB, Duke DC, Silverstein JH, Geffken GR. Brief report: normative data on a structured interview for diabetes adherence in childhood. J Pediatr Psychol. 2010;35(2):177–182. doi:10.1093/jpepsy/jsp055

81. Harris MA, Wysocki T, Sadler MIC, et al. Validation of a structured interview for the assessment of diabetes self-management. Diabetes Care. 2000;23(9):1301–1304.

82. Markowitz JT, Laffel LM, Volkening LK, et al. Validation of an abbreviated adherence measure for young people with Type1 diabetes. Diabet Med. 2011;28(9):1113–1117.